A Randomised, Placebo Controlled, Double-blind, Dose Escalation, Single Centre Trial to Evaluate the Safety and Immunogenicity of PnuBioVax Administered on Three Occasions 28 Days Apart at Three Dose Levels in Healthy Adult Subjects.

Trial Profile

A Randomised, Placebo Controlled, Double-blind, Dose Escalation, Single Centre Trial to Evaluate the Safety and Immunogenicity of PnuBioVax Administered on Three Occasions 28 Days Apart at Three Dose Levels in Healthy Adult Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Pneumococcal vaccine (Primary)
  • Indications Clostridium infections; Pneumonia
  • Focus Adverse reactions; First in man
  • Sponsors ImmunoBiology
  • Most Recent Events

    • 10 Nov 2017 Results published in the Vaccine
    • 04 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 30 Aug 2016 Planned End Date changed from 1 May 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top